Intellia Therapeutics General and Administrative Expenses | NTLA

General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.

What these expenses include

Salaries of administrative staff (executives, HR, accountants, legal personnel)
Office rent and utilities
Office equipment and IT infrastructure
Professional services (auditors, lawyers, consultants)
Insurance
General administrative travel and representation expenses

What the metric indicates

Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure
Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit
Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry
Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines

Annual General and Administrative Expenses Intellia Therapeutics

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
120 M	126 M	116 M	90.3 M	71.1 M	44.2 M	41.1 M	32.2 M	28 M	16.8 M	8.28 M	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
126 M	8.28 M	63.1 M

Quarterly General and Administrative Expenses Intellia Therapeutics

2026-Q2	2026-Q1	2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
37.8 M	34.8 M	30.5 M	27.2 M	29 M	-	30.5 M	31.8 M	31.1 M	-	29.4 M	30.7 M	27.4 M	-	22.1 M	22.1 M	22.4 M	-	18.7 M	16.7 M	13.6 M	10.8 M	10.6 M	11.5 M	11.3 M	8.98 M	8.43 M	13.1 M	10.5 M	8.71 M	8.27 M	7.8 M	7.41 M	10.2 M	5.71 M	6.37 M	5.73 M	5.12 M	4.7 M	3.73 M	3.25 M	2.81 M	1.53 M	2.83 M	1.11 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
37.8 M	1.11 M	15.3 M

General and Administrative Expenses of other stocks in the Biotechnology industry

Issuer	General and Administrative Expenses	Price	% 24h	Market Cap	Country
AnaptysBio ANAB	23.4 M	$ 51.0	1.83 %	$ 1.48 B	USA
Allakos ALLK	38.8 M	-	-	$ 28.6 M	USA
Black Diamond Therapeutics BDTX	16.6 M	$ 1.88	0.53 %	$ 107 M	USA
Clovis Oncology CLVS	33.3 M	-	-7.23 %	$ 13 M	USA
Concert Pharmaceuticals CNCE	22.5 M	-	-	$ 401 M	USA
Evelo Biosciences EVLO	29.9 M	-	-14.46 %	$ 27.9 M	USA
BioMarin Pharmaceutical BMRN	1.15 B	$ 60.26	0.06 %	$ 11.6 B	USA
BioNTech SE BNTX	514 M	$ 98.52	0.24 %	$ 23.8 B	Germany
Can-Fite BioPharma Ltd. CANF	3.66 M	$ 2.17	0.46 %	$ 3.57 M	Israel
Freeline Therapeutics Holdings plc FRLN	30.7 M	-	-	$ 384 M	Britain
Genocea Biosciences GNCA	14.7 M	-	-15.0 %	$ 3.04 M	USA
Catalyst Biosciences CBIO	20.8 M	$ 13.99	0.84 %	$ 1.25 B	USA
C4 Therapeutics CCCC	36.2 M	$ 2.98	0.3 %	$ 247 M	USA
Codexis CDXS	47.1 M	$ 1.32	1.09 %	$ 115 M	USA
Amryt Pharma plc AMYT	92 M	-	-	$ 621 M	Britain
Cerus Corporation CERS	80.9 M	$ 2.62	0.38 %	$ 499 M	USA
G1 Therapeutics GTHX	71.1 M	-	-	$ 370 M	USA
Coherus BioSciences CHRS	101 M	$ 1.13	0.43 %	$ 132 M	USA
Celldex Therapeutics CLDX	43.8 M	$ 31.1	1.16 %	$ 2.07 B	USA
CollPlant Biotechnologies Ltd. CLGN	4.83 M	$ 4.25	3.16 %	$ 51.9 M	Israel
Cellectar Biosciences CLRB	11.5 M	$ 1.8	0.72 %	$ 4.69 M	USA
AbbVie ABBV	14 B	$ 264.34	0.09 %	$ 468 B	USA
Humanigen HGEN	15.6 M	-	-81.12 %	$ 4.28 M	USA
Cocrystal Pharma COCP	3.96 M	$ 1.17	1.74 %	$ 13.2 M	USA
AbCellera Biologics ABCL	83.2 M	$ 12.7	0.4 %	$ 3.79 B	Canada
Abeona Therapeutics ABEO	65 M	$ 5.4	2.65 %	$ 286 M	USA
Collegium Pharmaceutical COLL	67.6 M	$ 22.53	0.2 %	$ 713 M	USA
Corcept Therapeutics Incorporated CORT	449 M	$ 116.1	4.93 %	$ 12.1 B	USA
Фармсинтез LIFE	24.1 M	-	-	-	Russia
IGM Biosciences IGMS	50.4 M	-	-	$ 76.9 M	USA
IMV IMV	17 M	-	-	$ 13.1 M	Canada
Kinnate Biopharma KNTE	28.2 M	-	-	$ 123 M	USA
Cardiff Oncology CRDF	14.2 M	$ 1.24	0.74 %	$ 82.9 M	USA
Checkmate Pharmaceuticals CMPI	15.7 M	-	-	$ 231 M	USA
Corbus Pharmaceuticals Holdings CRBP	15.2 M	$ 7.14	0.19 %	$ 95.1 M	USA
Karuna Therapeutics KRTX	131 M	-	-	$ 12.2 B	USA
Curis CRIS	14 M	$ 0.83	1.1 %	$ 10.9 M	USA
CorMedix CRMD	68.2 M	$ 7.85	1.03 %	$ 565 K	USA
Crinetics Pharmaceuticals CRNX	191 M	$ 84.95	0.13 %	$ 7.99 B	USA
CRISPR Therapeutics AG CRSP	73.5 M	$ 54.23	0.23 %	$ 4.88 B	Schweiz
Champions Oncology CSBR	11.2 M	$ 4.9	0.1 %	$ 67.8 M	USA
Chimerix CMRX	22.2 M	-	-	$ 756 M	USA
Corvus Pharmaceuticals CRVS	9.25 M	$ 11.62	8.21 %	$ 918 M	USA
Cue Biopharma CUE	16.2 M	$ 31.41	1.45 %	$ 2.98 B	USA
CEL-SCI Corporation CVM	8.92 M	$ 1.67	2.38 %	$ 13.4 M	USA
Arbutus Biopharma Corporation ABUS	15.9 M	$ 4.85	0.2 %	$ 929 M	Canada
Cytokinetics, Incorporated CYTK	284 M	$ 64.66	0.17 %	$ 7.77 M	USA
Daré Bioscience DARE	8.76 M	$ 0.78	4.73 %	$ 8.72 M	USA
Adagene ADAG	7.08 M	$ 2.93	2.86 %	$ 173 M	China
DiaMedica Therapeutics DMAC	9.78 M	$ 7.94	1.4 %	$ 373 M	USA